MarketPulse

rare diseases

8 articles
The Motley FoolThe Motley Fool··Jonathan Ponciano

Boone Capital Exits 372% Biotech Winner to Chase Emerging Clinical Plays

Boone Capital liquidates entire $13.57M Cogent Biosciences stake despite 372% gain, reallocating to earlier-stage biotech plays like TYRA. Strategic rebalancing in volatile sector.
MDTTYRAIONSCOGTBMRN+2biotechclinical-stage
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Biodexa Pharmaceuticals Executes 1-for-5 Reverse ADR Split to Maintain Nasdaq Listing

Biodexa Pharmaceuticals executes 1-for-5 reverse ADR split effective April 6, 2026, to maintain Nasdaq listing compliance with minimum bid price requirements.
BDRXbiopharmaceuticalrare diseases
Investing.comInvesting.com··Gurufocus

Catalyst Pharmaceuticals Trades at Deep Discount Despite Strong Cash Generation

Catalyst Pharmaceuticals trades at 20-33% discount to peers with 7.5% FCF yield; 2026 Hetero litigation is binary catalyst determining if shares reach $28-32 or collapse to $16-20.
CPRXpatent cliffvaluation discount
BenzingaBenzinga··Globe Newswire

BioCryst Grants 65,850 RSUs to New Hires Under Nasdaq Inducement Rule

BioCryst awards 65,850 RSUs to six new employees under Nasdaq inducement rule, vesting over four years starting March 2027.
BCRXrestricted stock unitsbiotechnology
BenzingaBenzinga··Globe Newswire

Palvella Therapeutics Raises $230M in Upsized IPO to Fund Rare Disease Pipeline

Palvella Therapeutics closed $230M public offering at $125/share on February 27, 2026, fully exercising underwriter options to fund rare skin disease programs.
PVLAclinical-stagepublic offering
BenzingaBenzinga··Globe Newswire

Larimar Therapeutics Raises $100M in Expanded Share Offering

Larimar Therapeutics raises $100M through expanded share offering at $5 per share, funding development of lead drug candidate nomlabofusp and operations.
LRMRpublic offeringcapital raise
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Larimar Therapeutics Raises $100M Through Expanded Public Offering

Larimar Therapeutics raises $100M through expanded public offering at $5 per share, funding clinical development of rare disease therapeutic candidate nomlabofusp.
LRMRclinical-stagepublic offering
The Motley FoolThe Motley Fool··Jonathan Ponciano

Commodore Capital Exits Majority Centessa Stake as Stock Rallies 53%

Commodore Capital exits majority Centessa stake, selling 1.85M shares for $46.86M amid 53% stock rally and company's strategic leadership changes.
CNTAbiotechclinical-stage